Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for ...
Crofelemer has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency for SBS and MVID. In October 2025, as announced, the company ...
Enrollment in company’s first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results